Interactions between Renin Angiotensin System and Advanced Glycation in the Kidney
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Although hemodynamic and metabolic factors are individually implicated in the development of diabetic nephropathy, their interaction has not been defined clearly. In this study, the effects of angiotensin II (Ang II) and advanced glycation end products (AGE) both individually on each other are explored and compared. In the first study arm, Sprague-Dawley rats received a continuous infusion of AGE-modified rat serum albumin (RSA) or unmodified RSA for 4 wk with or without the angiotensin receptor type 1 antagonist valsartan. In the second arm, animals received a continuous infusion of Ang II (58.3 ng/kg per min) with or without the AGE inhibitor pyridoxamine. Components of the intrarenal renin-angiotensin system were measured using real time reverse transcription-PCR, immunohistochemistry, and standard angiotensin-converting enzyme (ACE) activity assays. Renal and serum AGE were quantified by immunohistochemistry, ELISA, and AGE-fluorescence. After an infusion of AGE-RSA, renal expression of angiotensinogen, ACE, renin, and angiotensin receptor type 1 were increased significantly (all P < 0.01), and ACE activity was elevated. This was associated with tubular and glomerular hypertrophy and AGE accumulation, which could be antagonized by valsartan. However, valsartan had no effect on increased filtration fraction associated with an AGE-RSA infusion. At the same time, an infusion of Ang II increased the serum and renal accumulation of AGE and advanced oxidation protein products and induced renal hypertrophy and salt retention that could be antagonized by pyridoxamine. However, pyridoxamine had no effect on renal vasoconstriction manifested by reduced renal blood flow. AGE and Ang II have overlapping activities in the kidney. The beneficial effects of blockade of either pathway underline the importance of this interaction in diabetic renal disease and the aging kidney.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy
Cooper, M. E. (2001) · Diabetologia · doi:10.1007/s001250100000 · Cited by 375 · cited 2×
“However, neither metabolic nor hemodynamic stimuli act in isolation (1).”
BackgroundSelf-citationRole of Advanced Glycation End Products in Diabetic Nephropathy
Forbes, J. M., Cooper, M. E., Oldfield, M. D., & Thomas, M. C. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000077413.41276.17 · Cited by 351 · cited 1×
“Advanced glycation end products (AGE), formed after prolonged hyperglycemia and oxidative (carbonyl) stress, also have a wide range of chemical, cellular, and tissue effects implicated in diabetic nephropathy (3).”
BackgroundSelf-citationCefalu, W. T., Wang, Z. Q., Bell-Farrow, A., Kiger, F. D., & Izlar, C. (1994) · Clinical Chemistry · doi:10.1093/clinchem/40.7.1317 · Cited by 92
Cited by
The Role of Advanced Glycation End Products in Progression and Complications of Diabetes
Goh, S.-Y., & Cooper, M. E. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1817 · Cited by 987
“(86) have shown that pyridoxamine antagonizes angiotensin II-induced elevation in serum and renal AGEs, prevents renal hypertrophy, and decreases salt retention in experimental models.”
BackgroundSelf-citationInflammation and the pathogenesis of diabetic nephropathy
Wada, J., & Makino, H. (2013) · Clinical Science · doi:10.1042/cs20120198 · Cited by 775
A Glimpse of Various Pathogenetic Mechanisms of Diabetic Nephropathy
Kanwar, Y. S., Sun, L., Xie, P., Liu, F.-Y., & Chen, S. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.4.110807.092150 · Cited by 775
Diabetic Nephropathy: Mechanisms of Renal Disease Progression
Kanwar, Y. S., Wada, J., Sun, L., Xie, P., Wallner, E. I., Chen, S., Chugh, S., & Danesh, F. R. (2008) · Experimental Biology and Medicine · doi:10.3181/0705-mr-134 · Cited by 596
Brasacchio, D., Okabe, J., Tikellis, C., Balcerczyk, A., George, P., Baker, E. K., Calkin, A. C., Brownlee, M., Cooper, M. E., & El-Osta, A. (2009) · Diabetes · doi:10.2337/db08-1666 · Cited by 534
Self-citationSoro-Paavonen, A., Watson, A. M. D., Li, J., Paavonen, K., Koitka, A., Calkin, A. C., Barit, D., Coughlan, M. T., Drew, B. G., Lancaster, G. I., et al. (2008) · Diabetes · doi:10.2337/db07-1808 · Cited by 407
“Reflecting an activated vascular RAS, which is known to upregulate NADPH-oxidase– dependent reactive oxygen species (ROS) generation (22), diabetic apoE / mice had a marked increase in gene expression of the angiotensin II type 1a receptor (AT1a).”
BackgroundSelf-citationAdvanced Glycation end Products, Oxidative Stress and Diabetic Nephropathy
Yamagishi, S.-I., & Matsui, T. (2010) · Oxidative Medicine and Cellular Longevity · doi:10.4161/oxim.3.2.11148 · Cited by 397
Byun, K., Yoo, Y., Son, M., Lee, J., Jeong, G.-B., Park, Y. M., Salekdeh, G. H., & Lee, B. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.030 · Cited by 357
“In addition, pyridoxamine has been reported as preventing the Amadori reaction leading to AGEs formation (Adrover et al., 2008; Thomas et al., 2005).”
Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials
Calcutt, N. A., Cooper, M. E., Kern, T. S., & Schmidt, A. M. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2476 · Cited by 352
Self-citationPericyte Loss in Diabetic Retinopathy: Mechanisms and Consequences
Beltramo, E., & Porta, M. (2013) · Current Medicinal Chemistry · doi:10.2174/09298673113209990022 · Cited by 317
Diabetic nephropathy: diagnosis and treatment
Fineberg, D., Jandeleit-Dahm, K. A. M., & Cooper, M. E. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.184 · Cited by 295
Self-citationYamagishi, S.-I., Maeda, S., Matsui, T., Ueda, S., Fukami, K., & Okuda, S. (2012) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2011.03.014 · Cited by 294
Uremic Toxicity of Advanced Glycation End Products in CKD
Stinghen, A. E. M., Massy, Z. A., Vlassara, H., Striker, G. E., & Boullier, A. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014101047 · Cited by 242
Thomas, M. C., Pickering, R. J., Tsorotes, D., Koitka, A., Sheehy, K., Bernardi, S., Toffoli, B., Nguyen-Huu, T.-P., Head, G. A., Fu, Y., et al. (2010) · Circulation Research · doi:10.1161/circresaha.110.219279 · Cited by 232
Self-citationExpression of ACE and ACE2 in Individuals With Diabetic Kidney Disease and Healthy Controls
Mizuiri, S., Hemmi, H., Arita, M., Ohashi, Y., Tanaka, Y., Miyagi, M., Sakai, K., Ishikawa, Y., Shibuya, K., Hase, H., et al. (2008) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2007.11.022 · Cited by 218
Reiniger, N., Lau, K., McCalla, D., Eby, B., Cheng, B., Lu, Y., Qu, W., Quadri, N., Ananthakrishnan, R., Furmansky, M., et al. (2010) · Diabetes · doi:10.2337/db09-1766 · Cited by 177
“(37) have shown that advanced glycation end products can activate ACE and other components of the intra-renal renin-angiotensin system.”
BackgroundCoughlan, M. T., Thallas-Bonke, V., Pete, J., Long, D. M., Gasser, A., Tong, D. C. K., Arnstein, M., Thorpe, S. R., Cooper, M. E., & Forbes, J. M. (2007) · Endocrinology · doi:10.1210/en.2006-1300 · Cited by 124
“interactions, as assessed both in vitro and in vivo (20), between”
BackgroundSelf-citationTikellis, C., Pickering, R., Tsorotes, D., Du, X.-J., Kiriazis, H., Nguyen-Huu, T.-P., Head, G. A., Cooper, M. E., & Thomas, M. C. (2012) · Clinical Science · doi:10.1042/cs20110668 · Cited by 57
Self-citationReceptor for advanced glycation endproducts and progressive kidney disease
Fukami, K., Taguchi, K., Yamagishi, S.-I., & Okuda, S. (2015) · Current Opinion in Nephrology and Hypertension · doi:10.1097/mnh.0000000000000091 · Cited by 46
Metadata
- Authors
- Thomas, M. C., Tikellis, C., Burns, W. M., Bialkowski, K., Cao, Z., Coughlan, M. T., Jandeleit-Dahm, K., Cooper, M. E., & Forbes, J. M.
- Venue
- Journal of the American Society of Nephrology
- Published
- 2005-10
- Volume
- 16
- Issue
- 10
- Pages
- 2976-2984
- ISSN
- 1046-6673 (ISSN-L)
- OpenAlex
- W2160382989
- Cited by
- 136
- References
- 3
- FWCI
- 5.49
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.